bpc 157 and thymosin beta 4 combination study BPC-157 / TB-500 Blend (Dual Peptide) Thymosin Beta-4+BPC-157 Peptide Therapy -

Abstract Significance: The antiulcer peptide, stable gastric pentadecapeptide BPC 157 (previously employed in ulcerative colitis and multiple sclerosis trials, no reported toxicity (LD1 not achieved)), is reviewed, focusing on the particular skin wound therapy, incisional/excisional wound, deep burns, diabetic ulcers, and alkali burns, which may be generalized to the other tissues healing

Freezing can damage the peptide structure and create crystallization that makes the medication unreliable

Helps reduce weakness, fatigue and stress

Expected results and timeline GHK-CU works gradually through gene expression changes

Start with doses at the lower end of the dosing range as directed by physician